The short answer
BPC-157 corresponds to a fifteen-residue partial sequence of body protection compound, a protein reported in human gastric juice. The synthetic peptide is not isolated from the stomach. It is made by solid-phase synthesis from a sequence found there.
Key facts
- Source protein
- Body protection compound
- Found in
- Human gastric juice
- BPC-157
- A 15-residue partial sequence
- Production
- Solid-phase synthesis
- Not
- Extracted from gastric juice
- Reported property
- Stability in gastric juice
What was found where
The Zagreb group reported a protein in human gastric juice which they named body protection compound. BPC-157 is a fifteen-residue stretch of that protein's sequence, synthesised independently. The distinction matters: the peptide sold and studied is a synthetic construct, not a purified natural product.
Why gastric juice is an interesting place to look
It is one of the most chemically aggressive environments in the body: strongly acidic and rich in pepsin. Anything surviving there has properties worth understanding, and the stomach lining's ability to withstand its own secretions is a real physiological question. Looking for protective factors in that fluid is a reasonable research strategy.
Research material referenced
BPC-157 5mg, third-party HPLC tested
The stability claim this origin supports
The compound is routinely described as stable in human gastric juice, which is the specific property its name and its literature emphasise. Most peptides are destroyed there within minutes. If BPC-157 resists that, its proline content is a plausible structural explanation, since proline-adjacent bonds are poor substrates for most proteases including pepsin.
What a fragment relationship does not establish
That the fifteen-residue peptide does what the parent protein does. This is the same caution that applies to TB-500 and thymosin beta-4: a fragment is a different molecule, and activity of the parent does not transfer automatically. Here the parent protein is much less characterised than thymosin beta-4, so the comparison is harder to make in either direction.
Reading the origin claim carefully
Endogenous origin is frequently deployed as an argument for safety or naturalness. It establishes neither. A sequence occurring in a protein somewhere in the body says nothing about what happens when a fragment of it is synthesised and administered at a chosen concentration by a chosen route.
Frequently asked questions
- Is BPC-157 extracted from gastric juice?
- No. It is synthesised. The sequence corresponds to part of a protein reported in gastric juice.
- Is BPC-157 naturally occurring?
- The sequence occurs within a larger protein. The fifteen-residue peptide as such is a synthetic construct.
- Does the origin make it safe?
- No. Endogenous origin of a sequence says nothing about what a synthetic fragment does when administered.
Extended research context
The BPC-157 (Pentadecapeptide) deep dive
Deep dive: the pentadecapeptide sequence
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.
Two forms: acetate salt vs arginate
BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).
Reading a BPC-157 CoA
A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.
Research applications
- ▸Cell-culture models of gut epithelial integrity
- ▸Tendon fibroblast migration and collagen-synthesis assays
- ▸Angiogenesis models involving VEGF and NO signalling
- ▸Stability studies comparing acetate vs arginate salt forms
- ▸Analytical reference for pentadecapeptide HPLC methods
Handling checklist
- ✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
- ✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
- ✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
- ✓Protect from light and repeated warming
- ✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Mixing acetate and arginate BPC-157 across a study
Fix: Choose one salt form and stay with it. Different masses and solubility.
✗ Assuming stability at room temperature
Fix: Refrigerate reconstituted solution; discard after 28 days.
✗ Buying without a CoA
Fix: Only source from suppliers that publish batch HPLC + mass-spec data.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- What does BPC-157 stand for?
- Is BPC-157 the same as pentadecapeptide?
- Who discovered BPC-157?
- What is the difference between BPC-157 acetate and arginate?
- How is BPC-157 reconstituted for research?
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al. Pharmaceuticals (Basel) 2023 (PMID 37513963)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubMedNIH PubMed: Complete BPC-157 literature (Sikiric group)pubmed.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
The UK Peptides Editorial Team · Research library, UK Peptides
The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.
More BPC-157 (Pentadecapeptide) articles
- The Stability Claim, ExaminedThe literature calls it the stable gastric pentadecapeptide. What stability means here, what supports the claim, and what it does not imply.
- BPC-157 Storage, Stability and ReconstitutionProline-rich and free of cysteine and methionine, so enzymatically and chemically robust. Why gastric stability does not remove the need for cold, dry storage.
- BPC-157 Mechanism: Why It Is Described as Multi-PathwayReported effects span angiogenic signalling, growth-factor interactions and nitric oxide pathways. Why no single defining mechanism has emerged.
- BPC-157 and Blood VesselsVascular effects recur across the BPC-157 literature and offer the most plausible common thread linking its reported activity in different tissues.
- Tendon and Ligament ModelsKrivic on Achilles detachment and Cerovecki on ligament healing, both in the Journal of Orthopaedic Research. What rat models can and cannot establish.
Popular across the research hub
One flagship guide from every other research category.
- Retatrutide ResearchIs Retatrutide FDA Approved? Regulatory Status Explained
- GHK-Cu (Copper Peptide)GHK-Cu and Matrikine Signalling
- TB-500 (Thymosin β4 fragment)TB-500: Structure and Where It Comes From
- CJC-1295 & IpamorelinHow Ipamorelin Acts at the Ghrelin Receptor
- Peptide ReferenceAre Peptides Legal in the UK?
- Bacteriostatic WaterBenzyl Alcohol Is Not an Inert Excipient
- Research & Regulatory NewsSemaglutide in Obesity-Related Heart Failure
- GLP-1 & Incretin ScienceWhy Population-Specific Trials Are Run
- MOTS-c (Mitochondrial Peptide)The Structural Reasons the Evidence Is Thin
- Semax (ACTH Fragment Peptide)What a Fragment Keeps Decides What It Does
- Selank (Tuftsin Analogue)What an Aversive-Signs Model Measures
- DSIP (Delta Sleep-Inducing Peptide)DSIP in the Published Literature
- KLOW (Blend)Four Literatures, No Combination Literature
- GLOW (Blend)Synergy Is a Measurable Claim, Not an Assumption
- MT-2 (Melanotan II)Melanotan 2 Storage, Mixing and Stability
- IGF-1 LR3IGF-1 LR3 and Anti-Doping Status
- GlutathioneGlutathione in the Published Literature
- NAD+NAD+ Storage: Different Chemistry, Different Risks
- KPVKPV in the Published Literature